ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare ShareIss1Y Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FSHHHYPOTHETICAL MODEL
Since ’99
−14%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Oct 2022
placeholder
Full Sharpe
0.10
Ann. Return (LS)
2.4%
Ann. Volatility
23.5%
Max Drawdown
-70.1%
Test Sharpe ’19–26
0.27
Test FF5 α (ann.)
0.4%
vs Fama-French 5
Test FF5 α t-stat
0.06
not significant
Monthly turnover
9%
of the long leg, per rebalance
Cumulative return (LS)
-14%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.57
what this fund holds
Long leg ann. return
8.6%
buyable, long-only
Long-short Sharpe
0.10
requires shorting
Bottom bucket ann. return
6.3%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
31.85%
2MRK
MERCK & CO INCHealthcare$314.90B
9.03%
3TMO
THERMO FISHER SCIENTIFIC INCHealthcare$197.88B
5.67%
4GILD
GILEAD SCIENCES INCHealthcare$166.72B
4.78%
5DHR
DANAHER CORPHealthcare$144.26B
4.14%
6VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
3.53%
7ISRG
INTUITIVE SURGICAL INCHealthcare$122.33B
3.51%
8MCK
MCKESSON CORPHealthcare$101.14B
2.90%
9HCA
HCA HEALTHCARE INCHealthcare$82.34B
2.36%
10ELV
ELEVANCE HEALTH INCHealthcare$80.92B
2.32%
11CI
CIGNA GROUPHealthcare$74.45B
2.14%
12REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
2.03%
13CAH
CARDINAL HEALTH INCHealthcare$53.52B
1.53%
14EW
EDWARDS LIFESCIENCES CORPHealthcare$49.36B
1.42%
15IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
1.28%
16BDX
BECTON DICKINSON & COHealthcare$43.58B
1.25%
17A
AGILENT TECHNOLOGIES INCHealthcare$37.13B
1.06%
18IQV
IQVIA HOLDINGS INCHealthcare$34.42B
0.99%
19ZTS
ZOETIS INCHealthcare$32.10B
0.92%
20VEEV
VEEVA SYSTEMS INCHealthcare$31.74B
0.91%
21DXCM
DEXCOM INCHealthcare$29.58B
0.85%
22RMD
RESMED INCHealthcare$28.86B
0.83%
23GEHC
GE HEALTHCARE TECHNOLOGIES INCHealthcare$28.69B
0.82%
24ILMN
ILLUMINA INCHealthcare$28.24B
0.81%
25MTD
METTLER TOLEDO INTERNATIONAL INCHealthcare$26.47B
0.76%
26WST
WEST PHARMACEUTICAL SERVICES INCHealthcare$25.31B
0.73%
27DGX
QUEST DIAGNOSTICS INCHealthcare$23.32B
0.67%
28LH
LABCORP HOLDINGS INCHealthcare$23.24B
0.67%
29UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.65%
30STE
STERIS PLCHealthcare$21.26B
0.61%
31VTRS
VIATRIS INCHealthcare$20.14B
0.58%
32ZBH
ZIMMER BIOMET HOLDINGS INCHealthcare$17.63B
0.51%
33THC
TENET HEALTHCARE CORPHealthcare$16.79B
0.48%
34DVA
DAVITA INCHealthcare$15.21B
0.44%
35EXEL
EXELIXIS INCHealthcare$14.06B
0.40%
36COO
COOPER COMPANIES INCHealthcare$13.99B
0.40%
37ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
0.36%
38RVTY
REVVITY INCHealthcare$12.29B
0.35%
39MOH
MOLINA HEALTHCARE INCHealthcare$11.74B
0.34%
40PODD
INSULET CORPHealthcare$11.36B
0.33%
41EHC
ENCOMPASS HEALTH CORPHealthcare$11.13B
0.32%
42CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INCHealthcare$10.81B
0.31%
43HSIC
HENRY SCHEIN INCHealthcare$10.00B
0.29%
44HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.26%
45UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.26%
46ATR
APTARGROUP INCHealthcare$8.46B
0.24%
47TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.24%
48HQY
HEALTHEQUITY INCHealthcare$8.17B
0.23%
49BIO
BIO-RAD LABORATORIES INCHealthcare$8.15B
0.23%
50LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.20%
51CHE
CHEMED CORPHealthcare$6.77B
0.19%
52HNGE
HINGE HEALTH INCHealthcare$6.74B
0.19%
53CAI
CARIS LIFE SCIENCES INCHealthcare$4.66B
0.13%
54LFST
LIFESTANCE HEALTH GROUP INCHealthcare$4.49B
0.13%
55NVST
ENVISTA HOLDINGS CORPHealthcare$4.35B
0.12%
56DOCS
DOXIMITY INCHealthcare$3.94B
0.11%
57HAE
HAEMONETICS CORPHealthcare$3.54B
0.10%
58OPCH
OPTION CARE HEALTH INCHealthcare$3.41B
0.10%
59ITGR
INTEGER HOLDINGS CORPHealthcare$3.24B
0.09%
60ASTH
ASTRANA HEALTH INCHealthcare$2.50B
0.07%
61PGNY
PROGYNY INCHealthcare$2.50B
0.07%
62PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.07%
63MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.06%
64OMCL
OMNICELL INCHealthcare$2.09B
0.06%
65AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.06%
66CDNA
CAREDX INCHealthcare$2.05B
0.06%
67ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.06%
68HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.05%
69ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.05%
70INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.04%
71CNMD
CONMED CORPHealthcare$1.30B
0.04%
72CERT
CERTARA INCHealthcare$1.08B
0.03%
73PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.03%
74AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.02%
75HSTM
HEALTHSTREAM INCHealthcare$832M
0.02%
76CLYM
CLIMB BIO INCHealthcare$727M
0.02%
77EVH
EVOLENT HEALTH INCHealthcare$654M
0.02%
78TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.02%
79FLGT
FULGENT GENETICS INCHealthcare$573M
0.02%
80ARVN
ARVINAS INCHealthcare$517M
0.01%
81NRC
NRC HEALTHHealthcare$491M
0.01%
82VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.01%
83PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.01%
84DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.01%
85CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.01%
86EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.01%
87ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.01%
88ELMD
ELECTROMED INCHealthcare$349M
0.01%
89UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.01%
90KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.01%
91ANIK
ANIKA THERAPEUTICS INCHealthcare$203M
0.01%
92AMWL
AMERICAN WELL CORPHealthcare$199M
0.01%
93PDEX
PRO DEX INCHealthcare$183M
0.01%
94INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.01%
95JYNT
JOINT CORPHealthcare$127M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $3.49T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
17%10
31%24
50%20
<1%5
<1%7
<1%4
<1%11
<1%5
<1%5

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 66% toward Growth. +1% unclassified (4 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt99% → Large
SmallLarge
Value ↔ growth tilt66% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
2
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    68.4%
    Margin
    -6.6%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    31.8%
    Margin
    -6.8%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.2 (95% CI 0.7-1.4)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
11.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.17x
within
parametric
0.96x
within
cornish fisher
0.91x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 21%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2008
Before publication (pre-2008)
-0.04
Sharpe · -1.2% p.a.
January 1999December 2008 · 120 mo
Since publication
0.23
Sharpe · 4.4% p.a.
January 2009July 2026 · 211 mo
Change in Sharpe+0.27the return flipped from negative to positive since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
62%
16 of 26 3-year windows made money
Worst window
-0.77
Sharpe, August 2023 – July 2026
January 1999July 2026
Median Sharpe
0.20
Dispersion
0.60
Best window
1.87

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.32.3%-38.6%
3 yearsp.a.5.0%-20.0%
5 yearsp.a.4.4%1.6%
10 yearsp.a.8.8%3.4%
Since inceptionp.a.7.7%-0.6%
Calendar years
YearLong legLong-short
20267 mo5.5%-14.8%
202510.0%-32.5%
20240.9%-7.3%
2023-1.9%-13.6%
20220.9%79.7%
202125.4%82.1%
202014.8%4.5%
201919.2%-16.4%
20185.0%14.1%
201719.7%-9.0%
2016-1.0%24.9%
20157.2%-2.6%
201420.3%-14.7%
201342.0%-3.7%
201221.8%-5.1%
201110.9%8.2%
20108.3%5.4%
200922.4%5.5%
2008-21.4%5.0%
20074.5%-4.0%
20067.5%15.6%
200510.3%18.4%
20044.8%-5.7%
200311.3%-27.2%
2002-21.1%18.2%
2001-15.9%-4.9%
200048.2%-40.4%
1999-14.4%-13.4%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FSHH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-10-21 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$3.49T

Methodology

The Foundry Healthcare ShareIss1Y Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ShareIss1Y signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.